We continue to focus on research and development for other disease areas of significant need, always with an improved quality of life for patients in mind.
We are currently investigating a treatment for symptoms related to endometriosis and uterine fibroids—diseases that affect millions of women throughout the world. Both conditions are highly prevalent and are associated with a number of chronic complications.
Endometriosis is a painful disorder of the uterus that affects an estimated 176 million premenopausal women worldwide. We are working to help patients medically manage endometriosis and its often debilitating pain. As of February 2016, we have conducted the largest clinical trials in endometriosis to date, and continue to pursue a new treatment for the disease’s most common symptoms.
Uterine fibroids (also called leiomyomas or myomas) are noncancerous muscle tissue tumors of the uterus. Fibroids are most common in women aged 30-40 years and are associated with a number of painful symptoms. For women suffering from heavy menstrual bleeding associated with uterine fibroids, there are limited non-surgical treatments. We have several ongoing clinical studies evaluating the efficacy of a new treatment that helps manage the symptoms of uterine fibroids.
~1 in 10 women
of reproductive age are affected by endometriosis*
*Source: The World Endometriosis Research Foundation
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects between 70,000 and 100,000 patients worldwide. In the US and UK, average life expectancy is 35 to 40 years old. In countries such as El Salvador, India and Bulgaria, life expectancy drops to below 15. There currently is no cure for CF. We are currently evaluating investigational compounds in early clinical phases for a triple combination therapy.
Diabetic nephropathy, or diabetic kidney disease, is a common complication of diabetes and the leading cause of chronic kidney disease in the developing world. We are currently conducting a clinical study to assess the effects of an investigational drug on progression of kidney disease in patients with state 2 to 4 CKD and type 2 diabetes.